ClinicalTrials.gg
CompletedNCT05507450Updated May 9, 2025Results posted

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

A Phase 2 interventional study of V181 High-Potency Level and V181 Mid-Potency Level in Dengue Disease and Dengue Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 32 sites in 7 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,271
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid-Potency Level vaccine. This study will also evaluate the safety and tolerability of 3 different V181 potency level vaccines. The primary hypothesis of the study is that the V181 Low-Potency Level vaccine is non-inferior to the V181 Mid-Potency Level vaccine for each of the 4 dengue serotypes based on GMTs at Day 28 post-vaccination.

02

Conditions studied

  • Dengue Disease
  • Dengue Virus

Browse trials for

03

In context

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

This study's enrollment of 1,271 is above the median of 132 across 197 interventional studies indexed under Dengue.

Browse Dengue studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants are eligible to participate if they agree to the following for at least 90 days after administration of study intervention: Abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use unless confirmed to be azoospermic (vasectomized or secondary to medical cause).
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is NOT women of ; or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), or is abstinent from heterosexual intercourse as her preferred and usual lifestyle (abstinent on a long term and persistent basis), for at least 90 days after administration of study intervention. (Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.)

Exclusion criteria

Exclusion Criteria:

  • Has known history of dengue or zika natural infection.
  • Has an acute febrile illness (temperature ≥38.0°C [≥100.4°F] oral or equivalent) occurring within 72 hours before receipt of study vaccine or placebo.
  • Has a serious or progressive disease, including but not limited to cancer; uncontrolled diabetes; severe cardiac, renal, or hepatic insufficiency; or systemic or neurologic disorder.
  • Has known or suspected impairment of immunological function, including but not limited to congenital or acquired immunodeficiency, (HIV) infection, hematologic , or treatment for autoimmune diseases.
  • Has a condition in which repeated venipuncture or injections pose more than minimal risk for the participant, such as hemophilia, thrombocytopenia, other severe coagulation disorders, or significantly impaired venous access.
  • Has a known to any component of the study vaccine or placebo, or history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention.
  • Has received a dose of any dengue vaccine ( or approved) before study entry, or plans to receive any dengue vaccine (investigational or approved) for the duration of the trial.
  • Has received other licensed non- within 14 days before receipt of study vaccine or placebo, or is scheduled to receive any licensed non-live vaccine within 28 days following receipt of study vaccine or placebo. Exception: Inactivated influenza vaccine may be administered but must be given at least 7 days before receipt of study vaccine or placebo, or at least 28 days after receipt of study vaccine or placebo.
  • Has received a licensed live vaccine within 28 days before receipt of study vaccine or placebo, or is scheduled to receive any live vaccine within 28 days following receipt of study vaccine or placebo.
  • Has received systemic (equivalent of ≥2 mg/kg/day of prednisone or ≥20 mg/d for persons weighing >10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days before study entry or is expected to receive systemic corticosteroids at aforementioned dose and duration within 28 days following receipt of study vaccine or placebo. (Note: Topical and inhaled/nebulized steroids are permitted.)
  • Has received systemic corticosteroids exceeding physiologic replacement doses (approximately 5 mg/day prednisone equivalent) within 14 days before vaccination.
  • Has received therapies, including chemotherapeutic agents used to treat cancer or other conditions, treatments associated with organ or bone marrow transplantation, or autoimmune disease, within 6 months before receipt of study vaccine or placebo, or plans to receive immunosuppressive therapies within 28 days following receipt of study vaccine or placebo.
  • Has received a blood transfusion or blood products (including immunoglobulins) within 6 months before receipt of a study vaccine or placebo, or plans to receive a blood transfusion or blood products (including immunoglobulins) within 28 days following receipt of study vaccine or placebo.
  • Has participated in another clinical study of an investigational product within 6 months before signing the , or plans to participate in another interventional clinical study at any time during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case-by-case basis for approval by the Sponsor.
  • Has planned donation of blood, eggs, or sperm at any time from signing the informed consent through 90 days post-vaccination.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,271 participants (actual)

Study arms

  • Experimental
    V181 High-Potency Level Group

    Participants will receive a single 0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine.

    Biological: V181 High-Potency Level

  • Experimental
    V181 Mid-Potency Level Group

    Participants will receive a single 0.5mL SC dose of V181 Mid-Potency vaccine.

    Biological: V181 Mid-Potency Level

  • Experimental
    V181 Low-Potency Level Group

    Participants will receive a single 0.5mL SC dose of V181 Low-Potency vaccine.

    Biological: V181 Low-Potency Level

  • Placebo comparator
    Placebo

    Participants will receive a single SC 0.5 mL dose of placebo.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)

    A dengue VRNT was conducted to assess neutralizing antibody Geometric Mean Titers (GMTs) for each of the 4 dengue vaccine serotypes (DENV1, DENV2, DENV3, and DENV4) in specimens collected from participants on Day 28 post-vaccination.

    Time frame: Day 28 post-vaccination

  2. Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)

    An SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.

    Time frame: Up to 28 days post-vaccination

Secondary outcomes

  1. Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs include pain, erythema (redness), and swelling.

    Time frame: Up to 5 days post-vaccination

  2. Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include rash, headache, fatigue (tiredness), pyrexia (oral temperature ≥100.4 °F or 38.0 °C), myalgia (muscle pain), and arthralgia (joint pain).

    Time frame: Up to 28 days post-vaccination

07

Results

Posted May 9, 2025

Participant flow

Adult males or females, in generally good health, between 18 to 50 years of age, and without a history of dengue or Zika natural infection or prior receipt of any other dengue vaccine were enrolled in this study.

Participant flow — Overall Study
MilestoneV181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlacebo
Started231463461116
Vaccinated at baseline231461459115
Completed205430431106
Not completed26333010
Withdrew: Death0010
Withdrew: Lost to follow-up2220207
Withdrew: Randomized by mistake without study treatment0210
Withdrew: Withdrawal by subject41173
Withdrew: Participant left the country0010

Outcome measures

PrimaryDengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)

A dengue VRNT was conducted to assess neutralizing antibody Geometric Mean Titers (GMTs) for each of the 4 dengue vaccine serotypes (DENV1, DENV2, DENV3, and DENV4) in specimens collected from participants on Day 28 post-vaccination.

Time frame:
Day 28 post-vaccination
Reported as:
Geometric mean · Titer
Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)
TiterV181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlacebo
DENV1 Serotype326.31 (256.52 to 415.08)261.10 (220.90 to 308.61)184.85 (153.89 to 222.03)10.33 (8.79 to 12.14)
DENV2 Serotype815.79 (674.69 to 986.40)766.98 (683.66 to 860.45)854.59 (755.07 to 967.22)7.50 (7.50 to 7.50)
DENV3 Serotype203.04 (162.87 to 253.12)135.19 (115.70 to 157.97)94.69 (78.92 to 113.61)7.20 (6.11 to 8.48)
DENV4 Serotype102.13 (77.08 to 135.33)68.33 (55.80 to 83.67)64.43 (52.42 to 79.19)6.50 (6.50 to 6.50)
PrimaryPercentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)

An SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.

Time frame:
Up to 28 days post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)
Percentage of participantsV181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlacebo
Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)0.00.00.00.0
SecondaryPercentage of Participants With Solicited Injection-Site Adverse Events (AEs)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs include pain, erythema (redness), and swelling.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)
Percentage of participantsV181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlacebo
Injection site erythema35.521.715.01.7
Injection site pain34.219.713.514.8
Injection site swelling10.05.42.42.6
SecondaryPercentage of Participants With Solicited Systemic AEs

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include rash, headache, fatigue (tiredness), pyrexia (oral temperature ≥100.4 °F or 38.0 °C), myalgia (muscle pain), and arthralgia (joint pain).

Time frame:
Up to 28 days post-vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Systemic AEs
Percentage of participantsV181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlacebo
Fatigue52.848.644.033.9
Pyrexia10.87.65.70.9
Arthralgia21.212.613.17.8
Myalgia32.026.524.018.3
Headache54.549.946.247.0
Rash55.864.068.68.7

Adverse events

Collected over All-cause Mortality: Randomization up to 12 months post-vaccination; Serious Adverse Events: Vaccination up to 12 months post-vaccination; Non-Serious Adverse Events: Vaccination up to 28 Days post-vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V181 High-Potency Level0/231 (0%)8/231 (3.5%)200/231 (86.6%)
V181 Mid-Potency Level0/463 (0%)9/461 (2%)402/461 (87.2%)
V181 Low-Potency Level1/461 (0.2%)12/459 (2.6%)406/459 (88.5%)
Placebo0/116 (0%)6/115 (5.2%)79/115 (68.7%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventV181 High-Potency LevelV181 Mid-Potency LevelV181 Low-Potency LevelPlacebo
Tooth impactedGastrointestinal disorders0/2310/4610/4591/115
DiverticulitisInfections and infestations0/2310/4610/4591/115
Perineal abscessInfections and infestations0/2310/4610/4591/115
Scrotal abscessInfections and infestations0/2310/4610/4591/115
ChondromalaciaMusculoskeletal and connective tissue disorders0/2310/4610/4591/115
Neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2310/4610/4591/115
Suicidal ideationPsychiatric disorders0/2310/4610/4591/115
Suicide attemptPsychiatric disorders0/2310/4612/4590/115
GastroenteritisInfections and infestations1/2310/4610/4590/115
Herpes simplex encephalitisInfections and infestations1/2310/4610/4590/115
Most frequent other events
Showing 10 of 13
Most frequent other events
EventV181 High-Potency LevelV181 Mid-Potency LevelV181 Low-Potency LevelPlacebo
RashSkin and subcutaneous tissue disorders129/231295/461315/45910/115
HeadacheNervous system disorders126/231230/461212/45954/115
FatigueGeneral disorders122/231224/461202/45939/115
Injection site erythemaGeneral disorders85/231107/46176/4592/115
Injection site painGeneral disorders80/23191/46169/45918/115
MyalgiaMusculoskeletal and connective tissue disorders74/231122/461110/45921/115
ArthralgiaMusculoskeletal and connective tissue disorders49/23158/46160/4599/115
PyrexiaGeneral disorders25/23135/46126/4591/115
Injection site swellingGeneral disorders23/23125/46112/4593/115
NasopharyngitisInfections and infestations12/23131/46115/4594/115

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlaceboTotal
Mean33.8 ± 9.533.1 ± 9.833.3 ± 9.333.2 ± 9.133.3 ± 9.5
Sex/Gender, Customized
Sex/Gender, Customized(Participants)V181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlaceboTotal
Female12926526259715
Male10219819857555
Undifferentiated00101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlaceboTotal
Hispanic or Latino31515520157
Not Hispanic or Latino195396389941074
Unknown or Not Reported51617240
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V181 High-Potency Level GroupV181 Mid-Potency Level GroupV181 Low-Potency Level GroupPlaceboTotal
American Indian or Alaska Native10203
Asian153233686
Native Hawaiian or Other Pacific Islander13206
Black or African American51214940
White2074064001001113
More than one race21010123
Unknown or Not Reported00000
08

Study locations

32 sites
  • California Research Foundation ( Site 0114)
    San Diego, California 92123, United States
  • Advanced Medical Research Institute ( Site 0115)
    Miami, Florida 33174, United States
  • Rochester Clinical Research, Inc. ( Site 0122)
    Rochester, New York 14609, United States
  • University of Texas Medical Branch ( Site 0113)
    Galveston, Texas 77555, United States
  • IMA Clinical Research San Antonio ( Site 0111)
    San Antonio, Texas 78229, United States
  • Alliance for Multispecialty Research LLC (AMR - Norfolk) ( Site 0123)
    Norfolk, Virginia 23502, United States
  • Paratus Clinical Research Western Sydney ( Site 0007)
    Blacktown, New South Wales 2148, Australia
  • Emeritus Research ( Site 0010)
    Botany, New South Wales 2019, Australia
  • USC Clinical Trials Moreton Bay ( Site 0001)
    Morayfield, Queensland 4506, Australia
  • USC Clinical Trials Sunshine Coast ( Site 0005)
    Sippy Downs, Queensland 4556, Australia
  • USC Clinical Trials Brisbane (South Bank) ( Site 0006)
    South Brisbane, Queensland 4101, Australia
  • Emeritus Research ( Site 0009)
    Camberwell, Victoria 3124, Australia
  • Diex Recherche Joliette ( Site 0023)
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
  • Diex Recherche Sherbrooke Inc. ( Site 0024)
    Sherbrooke, Quebec J1L 0H8, Canada
  • Diex Recherche Victoriavile Inc. ( Site 0021)
    Victoriaville, Quebec G6P 6P6, Canada
  • Diex Recherche Quebec Inc. ( Site 0022)
    Quebec, G1V 4T3, Canada
  • FVR, Kokkolan rokotetutkimusklinikka ( Site 0037)
    Kokkola, Mellersta Osterbotten 67100, Finland
  • FVR, Tampereen rokotetutkimusklinikka ( Site 0039)
    Tampere, Pirkanmaa 33100, Finland
  • FVR, Oulun rokotetutkimusklinikka ( Site 0032)
    Oulu, Pohjois-Pohjanmaa 90220, Finland
  • FVR, Porin rokotetutkimusklinikka ( Site 0033)
    Pori, Satakunta 28100, Finland
  • FVR, Seinäjoen rokotetutkimusklinikka ( Site 0040)
    Seinajoki, Sodra Osterbotten 60100, Finland
  • FVR, Espoon rokotetutkimusklinikka ( Site 0036)
    Espoo, Uusimaa 02230, Finland
  • FVR, Etelä-Helsingin rokotetutkimusklinikka ( Site 0038)
    Helsinki, Uusimaa 00100, Finland
  • FVR, Itä-Helsingin rokotetutkimusklinikka ( Site 0035)
    Helsinki, Uusimaa 00930, Finland
  • FVR, Turun rokotetutkimusklinikka ( Site 0031)
    Turku, Varsinais-Suomi 20520, Finland
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Division of Infectious Diseases and Tropical (
    München, Bayern 80802, Germany
  • Berliner Centrum für Reise- und Tropenmedizin ( Site 0043)
    Berlin, 10117, Germany
  • Bernhard Nocht Institute for Tropical Medicine ( Site 0041)
    Hamburg, 20359, Germany
  • Rambam Health Care Campus-Oncology ( Site 0053)
    Haifa, 3109601, Israel
  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 0052)
    Jerusalem, 9112001, Israel
  • Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0051)
    Ramat Gan, 5265601, Israel
  • Kaohsiung Medical University Hospital-Infectious diseases Division, Department of Internal Medicine
    Kaohsiung, 807, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jun 2023, 8 months.

Results were first posted in May 2025, 1 year 11 months after primary completion. A results delay was requested in Mar 2024.

Of 21 industry-sponsored phase 2 interventional studies under Dengue, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 8 months is below that.

Counting every sponsor, half of 31 studies reached it within 20 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2022
First posted
Aug 19, 2022
StartActual
Sep 7, 2022
Primary completionActual
Jun 5, 2023
CompletionActual
May 7, 2024
Results delay requested
Mar 15, 2024
Results first posted
May 9, 2025
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05507450
Responsible party
Sponsor
First posted
Aug 19, 2022
Start date
Sep 7, 2022
Primary completion
Jun 5, 2023
Completion
May 7, 2024
Results posted
May 9, 2025
Last update
May 9, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: V181

Start the discussion